04.30.13
Eddie Gray has been appointed chief executive officer and a member of the board at Dynavax Technologies Corp. Mr. Gray succeeds Dino Dina, M.D., who will remain a consultant to the company for a transition period and plans to continue serving as a board member. Also, president Tyler Martin, M.D., is leaving the company on May 31, 2013 and plans to remain a consultant for a transition period.
Most recently, Mr. Gray served as the president of Pharmaceuticals Europe at GlaxoSmithKline since 2008 and as senior vice president and general manager of Pharmaceuticals UK from 2001 through 2007. In both roles, he was instrumental in the launch, commercialization and strategic development of GSK's vaccine portfolio. Mr. Gray was previously with SmithKline Beecham in various positions of increasing responsibility.
"With 30 years of industry experience, Eddie has a track record of success in building international commercial organizations," said Dr. Dina. "His extensive executive and operations-based background position him to lead the company going forward, and he will be a major contributor to driving sustainable long-term value for Dynavax."
Most recently, Mr. Gray served as the president of Pharmaceuticals Europe at GlaxoSmithKline since 2008 and as senior vice president and general manager of Pharmaceuticals UK from 2001 through 2007. In both roles, he was instrumental in the launch, commercialization and strategic development of GSK's vaccine portfolio. Mr. Gray was previously with SmithKline Beecham in various positions of increasing responsibility.
"With 30 years of industry experience, Eddie has a track record of success in building international commercial organizations," said Dr. Dina. "His extensive executive and operations-based background position him to lead the company going forward, and he will be a major contributor to driving sustainable long-term value for Dynavax."
